Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); Q1 In-line; Waiting on P3 TIVO-1 Data at ASCO
Tweet Send to a FriendGet Alerts AVEO Hot Sheet
Price: $2.66 -8.28%
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
1 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade AVEO Now!
Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $14.00.
Analyst, Salveen Richter, said, "AVEO reported Q1/12 GAAP EPS of $(0.77), roughly in line with consensus of $(0.76) but below CGe of $(0.71). The call focused on ficlatuzumab P2 data in NSCLC, which was released yesterday, as well as management’s outlook for ASCO. We look toward full P3 TIVO-1 data at ASCO (June 2; 3pm-6pm; Chicago) – which will provide clarity on tivozanib’s efficacy and safety profile vs. the available drugs in RCC and in the context of new competitor data (PFE’s Inlyta) – to serve as the next catalyst for AVEO shares. The NDA filing remains on track for Q3/12." (Raising FY12 EPS estimate from $1.68 to $1.72)
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $11.55 yesterday, with a 52 week range of $10.40-$21.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Salveen Richter, said, "AVEO reported Q1/12 GAAP EPS of $(0.77), roughly in line with consensus of $(0.76) but below CGe of $(0.71). The call focused on ficlatuzumab P2 data in NSCLC, which was released yesterday, as well as management’s outlook for ASCO. We look toward full P3 TIVO-1 data at ASCO (June 2; 3pm-6pm; Chicago) – which will provide clarity on tivozanib’s efficacy and safety profile vs. the available drugs in RCC and in the context of new competitor data (PFE’s Inlyta) – to serve as the next catalyst for AVEO shares. The NDA filing remains on track for Q3/12." (Raising FY12 EPS estimate from $1.68 to $1.72)
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $11.55 yesterday, with a 52 week range of $10.40-$21.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- UPDATE: Exane BNP Paribas Downgrades BlackBerry (BBRY) to Underperform; Analyst Says Profit 'Drying Up'
- Compuware (CPWR) Estimates Trimmed, PT Raised at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
